Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
01 Outubro 2024 - 8:00AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
INMODE LTD.
(Exact name of registrant as specified in its charter)
Tavor Building, Sha’ar Yokneam
P.O. Box 533
Yokneam 2069206 Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
On October 1, 2024, InMode Ltd. (the “Company”)
issued a press release announcing that the Company and Shakil Lakhani have mutually agreed that Mr. Lakhani will resign from his position as President of North America effective immediately. The mutual decision for Mr. Lakhani to resign was not related
to any disagreement between Mr. Lakhani and the Company relating to the Company’s operations, policies or practices.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
Exhibit No.
|
Description of Exhibit
|
|
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
| |
InMode Ltd.
|
| |
|
| |
By:/s/ Moshe Mizrahy
|
| |
Moshe Mizrahy
|
| |
Chief Executive Officer
|
Dated October 1, 2024
InMode Announces Departures of President of North America, Chief Medical
Officer and VP of Sales USA as Part of a Global Reorganization Strategy
YOKNEAM, Israel, October 1, 2024 --
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani, President of North America effective September 30, 2024. His departure follows that of Dr. Spero
Theodorou, Chief Medical Officer, and Dan Wilson, VP of Sales USA.
In addition to the departure of the three executives from InMode's North American operations, over the last few months, InMode has
changed the management teams in three of its subsidiaries in Europe: InMode UK, InMode Iberia and InMode France.
These changes come as part of InMode's ongoing effort to establish an optimal company structure that aligns with its global expansion
and penetration into new business verticals. As the Company continues to expand into the wellness sector, it has become clear that a reorganization is necessary to ensure that InMode has the right structure, and skill sets in place to support future
goals.
InMode has a full pipeline of new platforms, with over a dozen already in the market and more on the horizon. To manage this growth
effectively, the role of President of North America will be divided into separate roles, each providing the focus needed for the Company’s evolving business landscape.
Moshe Mizrahy, InMode’s CEO, said, “This new structure is designed to enhance operational efficiency of our North American operations.
This reorganization marks an important step in InMode's evolution as a global company and demonstrates our commitment to building a robust infrastructure for future growth. I will be working closely with the executive team in North America to guide
this transition.
“We thank Shakil, Spero and Dan and wish them the best of luck in their future endeavors. We look forward to the exciting opportunities
ahead,” concluded Moshe Mizrahy.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing
novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of
products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
ir@inmodemd.com
917-607-8654
InMode (NASDAQ:INMD)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
InMode (NASDAQ:INMD)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
